Does genomic imprinting contribute to valproic acid teratogenicity?

Area of Science:

• Developmental biology
• Genetics
• Toxicology

Background:

• Valproic acid (VPA) is a known teratogen, causing birth defects.
• Genomic imprinting, a phenomenon of parent-specific gene expression, may influence VPA susceptibility.
• Mouse strains exhibit varying susceptibility to VPA-induced teratogenicity.

Purpose of the Study:

• To investigate the role of genomic imprinting in VPA teratogenicity.
• To determine if parental origin influences offspring susceptibility to VPA.
• To analyze the effects of VPA on fetal development, mortality, and weight in relation to imprinting.

Main Methods:

• Reciprocal crosses and backcrosses between VPA-resistant (C57BL/6J) and VPA-susceptible (SWV) mouse strains.
• Administration of a teratogenic dose of VPA to pregnant dams during gestation.
• Examination of fetuses for abnormalities (exencephaly), mortality, litter size, and weight at gestation day 18.

Main Results:

• Significant differences in exencephaly frequency were observed in backcrosses, consistent with genomic imprinting.
• Prenatal mortality patterns also supported the role of imprinting, particularly in crosses involving SWV dams.
• Fetal weight reduction in backcrosses involving SWV mice indicated imprinting effects.
• Three out of four investigated parameters showed results consistent with genomic imprinting.

Conclusions:

• Genomic imprinting plays a significant role in modulating susceptibility to valproic acid teratogenicity.
• Parental imprinting patterns, rather than direct maternal or paternal exposure alone, can predict offspring susceptibility to VPA.
• These findings highlight the complex genetic and epigenetic mechanisms underlying VPA-induced developmental toxicity.